Pilar Ciruela1, Conchita Izquierdo2, Sonia Broner3, Carmen Muñoz-Almagro4, Sergi Hernández5, Carmen Ardanuy6, Roman Pallarés7, Angela Domínguez8, Mireia Jané9. 1. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Roc Boronat 81-95, 08005 Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain. Electronic address: pilar.ciruela@gencat.cat. 2. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Roc Boronat 81-95, 08005 Barcelona, Spain. Electronic address: controlepidemiologic@gencat.cat. 3. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Roc Boronat 81-95, 08005 Barcelona, Spain. Electronic address: memergents@gencat.cat. 4. CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain; Hospital Universitario Sant Joan de Déu, P° Sant Joan de Déu 2, 08950 Esplugues, Barcelona, Spain; Department of Medicine, Universitat Internacional de Catalunya, Carrer Josep Trueta, s/n, 08195 Sant Cugat del Vallès, Barcelona, Spain. Electronic address: cma@hsjdbcn.org. 5. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Roc Boronat 81-95, 08005 Barcelona, Spain. Electronic address: snmc@gencat.cat. 6. Hospital Universitari de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain. Electronic address: c.ardanuy@bellvitgehospital.cat. 7. Hospital Universitari de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain. Electronic address: rpallares@ub.edu. 8. CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain; Departament de Medicina, Universitat de Barcelona, Casanova 143, 08036 Barcelona, Spain. Electronic address: angela.dominguez@ub.edu. 9. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Roc Boronat 81-95, 08005 Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain. Electronic address: mireia.jane@gencat.cat.
Abstract
BACKGROUND: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). METHODS: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006-2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006-2009) and PCV13 periods (2010-2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2-4 years, 5-64 years and ≥65 years. RESULTS: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2-4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2-4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2-4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. CONCLUSIONS: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.
BACKGROUND: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). METHODS: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006-2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006-2009) and PCV13 periods (2010-2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2-4 years, 5-64 years and ≥65 years. RESULTS: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2-4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2-4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2-4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. CONCLUSIONS: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.
Authors: Oluwaseun Rume-Abiola Oyewole; Phung Lang; Werner C Albrich; Kerstin Wissel; Stephen L Leib; Carlo Casanova; Markus Hilty Journal: Microorganisms Date: 2021-05-18
Authors: Julia C Bennett; Marissa K Hetrich; Maria Garcia Quesada; Jenna N Sinkevitch; Maria Deloria Knoll; Daniel R Feikin; Scott L Zeger; Eunice W Kagucia; Adam L Cohen; Krow Ampofo; Maria-Cristina C Brandileone; Dana Bruden; Romina Camilli; Jesús Castilla; Guanhao Chan; Heather Cook; Jennifer E Cornick; Ron Dagan; Tine Dalby; Kostas Danis; Sara de Miguel; Philippe De Wals; Stefanie Desmet; Theano Georgakopoulou; Charlotte Gilkison; Marta Grgic-Vitek; Laura L Hammitt; Markus Hilty; Pak-Leung Ho; Sanjay Jayasinghe; James D Kellner; Jackie Kleynhans; Mirjam J Knol; Jana Kozakova; Karl G Kristinsson; Shamez N Ladhani; Laura MacDonald; Grant A Mackenzie; Lucia Mad'arová; Allison McGeer; Jolita Mereckiene; Eva Morfeldt; Tuya Mungun; Carmen Muñoz-Almagro; J Pekka Nuorti; Metka Paragi; Tamara Pilishvili; Rodrigo Puentes; Samir K Saha; Aalisha Sahu Khan; Larisa Savrasova; J Anthony Scott; Anna Skoczyńska; Shigeru Suga; Mark van der Linden; Jennifer R Verani; Anne von Gottberg; Brita A Winje; Inci Yildirim; Khalid Zerouali; Kyla Hayford Journal: Microorganisms Date: 2021-03-27